Project Grant R01AI184546
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of South Florida a $791,245 Project Grant effective May 6, 2026, through the Allergy and Infectious Diseases Research program (CFDA 93.855) to support fundamental biomedical research on placental antiviral defense mechanisms. The research, conducted through a collaborative effort between the Totary-Jain and Coyne laboratories, will elucidate how human trophoblasts (placental barrier cells) produce Type III...
- This $550,000 Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development and validation of a non-invasive, multiplex blood test for the early detection of preeclampsia, a serious pregnancy complication. The project aims to advance the detection of vascular dysfunction, particularly preeclampsia, by optimizing a blood test that targets disease-inducing signaling proteins on the surface of...
- The University of Michigan, as the primary recipient of this $598,644 Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), will conduct a longitudinal research study to develop and validate a non-invasive ultrasound-based diagnostic technique for detecting preeclampsia and fetal growth restriction. The research leverages spectral analysis of umbilical venous pulse wave...
- The University of California, San Diego received a $600,016 Project Grant award from the National Institute of Child Health and Human Development under the Child Health and Human Development Extramural Research program (CFDA 93.865), effective June 1, 2026 through February 28, 2031. This research initiative focuses on investigating extracellular vesicles (EVs) as mediators of kidney damage in preeclampsia, a hypertensive disorder affecting 2-10% of pregnant women and responsible for...
- This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) provides $485,925 to the University of Massachusetts Boston to develop novel antioxidant compounds for treating preeclampsia, a life-threatening pregnancy complication. The primary goal is to design and synthesize cationic hydrazone antioxidants that can target mitochondria to reduce oxidative stress, improve...
- Federal Grant Award Summary The University of California, San Diego received a $452,000 Project Grant from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), awarded August 1, 2025, with completion by July 31, 2027. This research project aims to identify a cellular immune signature unique to clinically-significant villitis of unknown etiology (VUE), a chronic inflammatory placental lesion...
- This National Science Foundation (NSF) Engineering (CFDA 47.041) Project Grant award to Worcester Polytechnic Institute (WPI) in the amount of $259,570 will develop 3D spheroid models using patient-derived trophoblast cells to investigate placental cell invasion and study preeclampsia, a pregnancy complication with high global maternal and infant mortality rates. The 2-year project will design culture conditions to maintain the spheroid models, engineer an extracellular matrix to mimic the...
- The National Institute of Child Health and Human Development (NICHD) awarded a $411,125 Project Grant (CFDA 93.865 - Child Health and Human Development Extramural Research) to Syracuse University to develop a microfluidic human placenta organoid model. The goal is to generate human trophoblast stem cells (HTSCs) from induced pluripotent stem cells and use them to create a placenta organoid system that can replicate early/mid-gestation placental development. The researchers will study the role of...
- This Project Grant award from the Department of Health and Human Services National Institutes of Health National Institute of Child Health and Human Development provides $769,916 to Emergent Biotechnologies LLC for research into a novel therapy for preeclampsia. The funding supports Phase 1 of developing and characterizing a handle region peptide as an innovative treatment for preeclampsia under the Child Health and Human Development Extramural Research program (CFDA 93.865). Phase 1 work will...
- Federal Project Grant Award Summary Mayo Clinic received a $443,850 Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), effective August 1, 2025, through July 31, 2027. The award funds research to define the role of human leukocyte antigen (HLA) haplotypes and immune rejection pathways in chronic villitis of unknown etiology (VUE), a placental inflammatory condition...
INNATE ALLORECOGNITION AT THE MATERNAL-FETAL INTERFACE - PREGNANCY IS A MATERNAL BALANCING ACT. TO GUARANTEE OPTIMAL LIFETIME REPRODUCTIVE SUCCESS, THE MOTHER MUST PARTITION HER RESOURCES BETWEEN CURRENT AND FUTURE PREGNANCIES. TOO LITTLE INVESTMENT IN THE CURRENT PREGNANCY COMPROMISES FETAL SURVIVAL, WHILE TOO MUCH INVESTMENT LOWERS LIFETIME REPRODUCTIVE SUCCESS BY COMPROMISING FUTURE PREGNANCIES. WE HYPOTHESIZE HERE THAT IMMUNE SYSTEM GENES THAT ENCODE ACTIVATING AND INHIBITORY ALLORECOGNITION RECEPTORS ON MYELOID CELLS SET THE OPTIMUM BY BALANCING THE MATERNAL ALLOIMMUNE RESPONSE AT THE MATERNAL-FETAL INTERFACE. ACTIVATING RECEPTORS LIMIT TROPHOBLAST INVASION AND REDUCE MATERNAL COST WHILE INHIBITORY RECEPTORS EXERT AN OPPOSITE EFFECT, RESULTING IN AN OPTIMAL BALANCE. WE ALSO HYPOTHESIZE THAT DISRUPTING THE BALANCE IN EITHER DIRECTION (IN FAVOR OF THE MOTHER OR IN FAVOR OF THE FETUS) INCREASES THE RISK OF GESTATIONAL DISORDERS SUCH AS PREECLAMPSIA. WE WILL FOCUS ON ALLORECOGNITION RECEPTORS EXPRESSED ON MONOCYTES AND MACROPHAGES THAT REGULATE THE ALLOIMMUNE RESPONSE TO TRANSPLANTED ORGANS BUT HAVE NOT BEEN PREVIOUSLY STUDIED IN GESTATION. IN AIM 1, WE WILL TEST THE HYPOTHESES IN MICE BY INVESTIGATING THE EFFECT OF DELETING THESE RECEPTORS ON THE DECIDUAL IMMUNE LANDSCAPE, TROPHOBLAST INVASION, PLACENTAL FUNCTION, AND REPRODUCTIVE SUCCESS, AND ASSESS IF THIS RESULTS IN PREECLAMPSIA-LIKE FEATURES. IN AIM 2, WE WILL TEST THE HYPOTHESES IN HUMANS BY INVESTIGATING THE ASSOCIATION BETWEEN PREECLAMPSIA AND A MATERNAL-FETAL MISMATCH IN THE POLYMORPHIC GENE ENCODING ONE OF THESE RECEPTORS THAT FAVORS MATERNAL MYELOID CELL ACTIVATION. PARTICULAR ATTENTION WILL BE PAID TO THE LIKELY DIVERGENCE OF THE IMMUNOPATHOGENESIS OF EARLY AND LATE PREECLAMPSIA, WHICH DIFFER DRAMATICALLY IN PLACENTAL PATHOLOGY AND EFFECTS ON FETAL GROWTH. THIS GRANT PROPOSAL BRINGS TOGETHER TRANSPLANT IMMUNOLOGISTS, REPRODUCTIVE BIOLOGISTS, AND PREECLAMPSIA EXPERTS TO EXECUTE THE PROPOSED AIMS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $656.1k | 6/9/26 | ||
| Not listed | $0 | 2/19/26 | ||
| Not listed | $0 | 2/19/26 | ||
| Not listed | $669.6k | 12/30/25 | ||
| Not listed | $669.6k | 12/30/25 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
63985546351259S | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Project Grant R01AI184546 | $100.6k | 6/22/26 | |
139889S | Magee-Womens Research Institute And Foundation | Project Grant R01AI184546 | $132.0k | 2/7/25 |